Quickly sort and find the exact file you need here. Send the files directly into your Shareholder Briefcase or read and right click "save target as" individual files.
| Title | Date | Type | Size | ||||
|---|---|---|---|---|---|---|---|
| Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Presentation | Aug 13, 2010 |
|
1.7 MB | ||||
| Corporate Fact Sheet | August 2010 |
|
1.1 MB | ||||
| Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares | Jun. 9, 2010 |
|
532.3 KB | ||||
| 2009 Annual Report and 10K | 2010 |
|
3.5 MB | ||||
| 2010 1st Quarter 10-Q | Apr 29, 2010 |
|
487.8 KB | ||||
| 2009 Form 10-K | Feb 18, 2010 |
|
2.5 MB | ||||
| 2010 Proxy Statement | 2010 |
|
560.1 KB | ||||
| 2009 3rd Quarter 10-Q | Nov 3, 2009 |
|
599.7 KB | ||||
| Senior Management Bios |
|
188.8 KB | |||||
| ARCALYST® Full Prescribing Information |
|
1.0 MB | |||||
|
|||||||
Stock Information
| NASDAQ:REGN
$23.28 + 0.80 |
Sep 2, 2010
11:32 AM ET |
Quotes delay at least 20min., by eSignal.
